INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Pulmonary & Nasal Drug Delivery
158
Issue No #158 Apr 2024
April 20th, 2024
Download PDF
Issue 158 - Apr 2024
Inside the magazine
EXPERT VIEW
Dr Zaid Aqrawe
Merxin Ltd
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.
NASAL
Alain Regard
Nemera
ADDRESSING CNS THERAPIES THROUGH NOSE-TO-BRAIN PATHWAYS
Alain Regard, Raphaële Audibert and Audrey Chandra, discuss the advantages of nasal delivery and highlight the challenges of the nose-to-brain pathways.
NASAL
Shai Assia
Clexio Biosciences
HUMAN FACTORS IN THE ABSENCE OF A FAMILIAR MENTAL MODEL: CHALLENGES & OPPORTUNITIES IN DRUG SELF-ADMINISTRATION
Shai Assia explores the intricate challenge of designing drug-device combination products for self-administration by lay users without medical expertise, focusing on targeted nasal drug delivery devices.
INTERVIEW
Dr Julie Suman
Aptar Pharma
Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT
Julie Suman discusses nasal casts, their development, applications and significance for nasal drug product development.
INDUSTRIALISATION
Marcus Jarman-Smith
Victrex
ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
Marcus Jarman-Smith and Yann Tréguier, discuss the myriad benefits that Victrex’s pharmaceutical-grade PEEK can offer to the drug delivery sector as a material of construction due to its versatile material properties.
PULMONARY
Dr Susana Saldanha
Hovione
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
Susana Saldanha, Lídia Santos and Rui Churro, discuss the benefits of crystalline formulations for inhalation devices.
INDUSTRIALISATION
Dr Alan Watts
Catalent Pharma Solutions
ARCUS
®
: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
Alan Watts and Michael Tauber, discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS, used for the successfully commercialised Inbrija® dry powder inhaler, is a prime example of this technology in action.
RESPIRATORY
Gemma Budd
Aptar Pharma
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.
PULMONARY
Matthew Fenn
Copley Scientific
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.
INTERVIEW
Dr Sandy Munro
Phillips Medisize
Interview with Sandy Munro, Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials.
PULMONARY
Gesa Braunlich
PARI
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
Gesa Bräunlich and Michael Hahn discuss PARI’s new eFlow integrated nebuliser.
RESPIRATORY
Mike Needham
Kindeva
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
Mike Needham takes a look at the history of, and progress in, inhalation technology and discusses what might lie ahead.
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
EXPERT VIEW
Dr Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
Top
